Bruton tyrosine kinase

Bru·ton tyrosine kinase (Btk),

an intracellular enzyme involved in B-cell signaling. Congenital deficiency of Btk occurs in X-linked agammaglobulinemia (XLA).
[Ogden C. Bruton]

BTK

A gene on chromosome Xq21.33-q22 that encodes a protein which plays a central role in B-cell development, differentiation and signalling. Binding of antigens to the B-cell antigen receptor (BCR) triggers signalling that leads to B-cell activation. 

Molecular pathology
Defects of BTK cause X-linked agammaglobulinaemia (OMIM:300755), as well as X-linked hypogammaglobulinaemia and isolated growth hormone deficiency (OMIM:307200).
References in periodicals archive ?
GENEVA -- An oral reversible Bruton tyrosine kinase inhibitor known as PRN1008 showed promising efficacy and safety for the treatment of pemphigus vulgaris in an interim analysis of an ongoing small-to-date, open-label phase 2 study according to DeDee Murrell, MD.
PRN1008 is a highly potent and selective inhibitor of Bruton tyrosine kinase (BTK), an enzyme that plays a major role in the signaling pathway running downstream from B cells to the B-cell receptors found on most white blood cells with the exception of T cells and plasma cells.
Seventy-five percent of Bruton tyrosine kinase receptors were occupied by PRN1008 by day 2 of the study, confirming earlier studies in canine models of pemphigus.
It was reported yesterday that the US Food and Drug Administration (USFDA) has granted priority review to AstraZeneca, an Anglo-Swedish multinational pharmaceutical and biopharmaceutical company, over a new drug application for its Bruton tyrosine kinase inhibitor, acalabrutinib.
Acalabrutinib is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor in development for the treatment of multiple B-cell cancers.
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency with more than 600 mutations in Bruton tyrosine kinase (Bkt) gene which are responsible for early-onset agammaglobulinemia and repeated infections.
Keywords: Bruton type agammaglobulinemia, Bruton tyrosine Kinase mutation, Whole exome sequencing, Diarrhoea.
Early changes in cytokines, chemokines, and indices of bone metabolism from phase 2 study of Bruton tyrosine kinase (Btk) inhibitor, Ibrutinib (PCI-32765) in subjects with relapsed or relapsed/refractory multiple myeloma (MM)
The product is a proprietary Bruton tyrosine kinase inhibitor intended to treat B-cell malignancies.
23 October 2014 - US cancer genetic testing service provider NeoGenomics Inc (NASDAQ:NEO) disclosed Thursday the launch of new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors, as well as the launch of a lymphoma profiling test predicting susceptibility to BTK inhibitors and testing for mutations in CXCR4, CD79B, MYD88, and CARD11 genes in various types of lymphoma.
The collaboration will see Abbott developing a FISH-based test to identify high-risk CLL patients who have a deletion within a specific chromosome (chromosome 17p (del17p)) and may respond to ibrutinib, an oral, small molecule inhibitor of Bruton tyrosine kinase (BTK).